Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly GLP-1 receptor agonist injections for type 2 diabetes. They share the same drug class but use different molecules with different potencies. In the head-to-head SUSTAIN-7 trial, Ozempic produced greater A1C reduction and weight loss than Trulicity. Both have cardiovascular risk reduction indications. Which is right for you depends on glycemic targets, weight goals, cardiovascular risk profile, injection device preference, and insurance coverage.
Side-by-Side Comparison
| Feature | Trulicity | Ozempic |
|---|---|---|
| Generic name | Dulaglutide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA indication | Type 2 diabetes; CV risk reduction in T2D | Type 2 diabetes; CV risk reduction in T2D + CVD |
| Dose range | 0.75 to 4.5 mg weekly | 0.25 to 2 mg weekly |
| Frequency | Weekly SC injection | Weekly SC injection |
| Pen type | Single-dose autoinjector — no needle handling | Multi-dose pen with screw-on needles |
| A1C reduction (max dose) | ~1.5 percentage points (4.5 mg) | ~2.0 percentage points (2 mg) |
| Weight loss (typical) | ~3 to 4 kg | ~4 to 7 kg |
| Cardiovascular outcomes trial | REWIND (12% MACE reduction) | SUSTAIN-6 (26% MACE reduction) |
| CV trial population | Primary + secondary prevention | Mostly secondary prevention |
| Approval year | September 2014 | December 2017 |
| List price/month | ~$1,000 | ~$970 |
What Each One Is
Trulicity (dulaglutide) is a once-weekly subcutaneous injection that acts on the GLP-1 receptor. The pen is a single-use autoinjector — the needle is hidden, and patients simply press the device against the skin to deliver the dose. FDA-approved in 2014.
Ozempic (semaglutide) is a once-weekly subcutaneous injection that acts on the GLP-1 receptor. The pen is multi-dose with a small screw-on needle and a dose dial. FDA-approved in 2017.
Head-to-Head Trial — SUSTAIN-7
SUSTAIN-7 directly compared semaglutide and dulaglutide in 1,201 patients with type 2 diabetes inadequately controlled on metformin, over 40 weeks.
| Outcome | Semaglutide 0.5 mg | Dulaglutide 0.75 mg | Semaglutide 1 mg | Dulaglutide 1.5 mg |
|---|---|---|---|---|
| A1C reduction | 1.5% | 1.1% | 1.8% | 1.4% |
| Weight loss | 4.6 kg | 2.3 kg | 6.5 kg | 3.0 kg |
| A1C below 7.0% | 68% | 52% | 79% | 67% |
| Weight loss ≥ 5% | 44% | 23% | 63% | 30% |
Ozempic outperformed Trulicity on both A1C and weight at every dose pairing tested.
Cardiovascular Outcomes
Trulicity — The REWIND trial (9,901 patients, 5.4-year follow-up) showed a 12 percent reduction in major adverse cardiovascular events. Importantly, only about 31 percent of REWIND patients had established cardiovascular disease — the rest had cardiovascular risk factors only — making REWIND the largest GLP-1 trial to demonstrate benefit in primary prevention.
Ozempic — The SUSTAIN-6 trial (3,297 patients) showed a 26 percent reduction in MACE. Most patients had established cardiovascular disease, so the indication is strongest in secondary prevention. SELECT (2023) extended the cardiovascular benefit to higher-dose semaglutide (Wegovy) in obesity without diabetes.
When to Choose Trulicity
- Type 2 diabetes with cardiovascular risk factors but no established CVD — REWIND data are strongest here
- Needle anxiety or arthritis — the autoinjector is preferred
- Vision impairment that makes Ozempic pen dose dialing difficult
- Moderate A1C reduction (1.0 to 1.5 percentage points) is sufficient
- Insurance covers Trulicity but not Ozempic
When to Choose Ozempic
- Higher baseline A1C requiring stronger reduction (≥ 1.8 percentage points)
- Greater weight loss is desired alongside diabetes control
- Established cardiovascular disease — SUSTAIN-6 indication
- Insurance covers Ozempic but not Trulicity
- Comfortable with multi-dose pens
Side Effects (Both)
- Nausea — most common, peaks in early titration
- Vomiting, diarrhea
- Constipation
- Abdominal pain
- Decreased appetite
- Fatigue
- Injection site reactions
- Gallbladder issues (cholelithiasis, cholecystitis)
- Pancreatitis (rare)
- Acute kidney injury (typically dehydration-driven)
- Boxed warning for thyroid C-cell tumors; contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2
Dosing Schedules
Trulicity — Start at 0.75 mg weekly; can increase to 1.5 mg after 4 weeks; further increases to 3 mg and 4.5 mg are allowed at 4-week intervals if needed for additional glycemic control.
Ozempic — Start at 0.25 mg weekly for 4 weeks (titration dose only); increase to 0.5 mg for at least 4 weeks; may increase to 1 mg and then 2 mg at 4-week intervals if needed.
Cost and Coverage
List prices are similar — about $1,000/month for Trulicity and $970/month for Ozempic. Both have manufacturer savings cards. Insurance coverage varies by plan; some plans prefer one over the other based on rebate contracts. Most type 2 diabetes patients can get one or the other approved with prior authorization. Both are expensive without insurance — typically over $900/month cash price.
Switching Between Them
Switching is typically straightforward — discontinue the first drug and start the other at the lowest dose the following week. Most clinicians do not skip the starting dose even if the prior drug was at maximum, to limit GI side effects. No washout period is needed. Insurance often requires reauthorization.
Lifestyle Pairing
Both medications work best alongside diet and activity. Read more about treatment pathways and A1C goals.
The Bottom Line
Ozempic produces greater A1C reduction and weight loss than Trulicity in head-to-head data. Trulicity has the easier injection device — a button-press autoinjector with no needle handling — and a cardiovascular outcomes trial that demonstrated benefit in patients with risk factors only, not just established disease. Side effect profiles are similar. Cost and coverage are comparable. Talk to your doctor about which fits your A1C target, weight goals, cardiovascular profile, and injection preference. Either one is a reasonable choice for most patients with type 2 diabetes who need more than metformin.
